Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

Cited by papers we hold 10

• Mutant-selective degradation by BRAF-targeting PROTACs · 2021
  No notice
• A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS · 2020
  No notice
• Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase · 2019
  No notice
• Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance · 2018
  No notice
• Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1 · 2016
  No notice
• Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy · 2014
  No notice
• Phytoplasma Effector SAP54 Hijacks Plant Reproduction by Degrading MADS-box Proteins and Promotes Insect Colonization in a RAD23-Dependent Manner · 2014
  No notice
• High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells · 2012
  No notice
• Current Advances in Detection and Treatment of Babesiosis · 2012
  No notice
• Two-Dimensional Patterning by a Trapping/Depletion Mechanism: The Role of TTG1 and GL3 in Arabidopsis Trichome Formation · 2008
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.